Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanFRA:L74 -4.46%55 EV-to-OCF is 42.24 as of Sep. 01, 2026, which is 13% below its 10-year median of 48.55. GuruFocus rates FRA:L74 with a GF Score™ of 55/100. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks worse than 89.25% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, WuXi XDC Cayman's Enterprise Value is €9,119.2 Mil.
WuXi XDC Cayman's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €215.9 Mil. Therefore, WuXi XDC Cayman's EV-to-OCF for today is 42.24.
The historical rank and industry rank for WuXi XDC Cayman's EV-to-OCF or its related term are showing as below:
FRA:L74'
s EV-to-OCF Range Over the Past 10 Years
Min: 27.74 Med: 48.55 Max: 138.32
Current: 42.21
During the past 6 years, the highest EV-to-OCF of WuXi XDC Cayman was 138.32. The lowest was 27.74. And the median was 48.55.
FRA:L74's EV-to-OCF is ranked worse than 89.25% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.91
vs FRA:L74: 42.21
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WuXi XDC Cayman's PE Ratio (TTM) for today is calculated as:
WuXi XDC Cayman's share price for today is €7.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.144.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
WuXi XDC Cayman EV-to-OCF Related Terms
WuXi XDC Cayman EV-to-OCF Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's EV-to-OCF falls into.
WuXi XDC Cayman's current Enterprise Value is €9,119.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €215.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (FRA:L74) has a EV-to-OCF of 42.24 as of Sep. 01, 2026. This is 13% below median its historical median of 48.55. Over the past decade, WuXi XDC Cayman's EV-to-OCF has ranged from 27.74 to 138.32. According to the industry distribution chart, WuXi XDC Cayman ranks #191 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 89.3%.
Is WuXi XDC Cayman's EV-to-OCF too high?
WuXi XDC Cayman's current EV-to-OCF of 42.24 is 13% below median its 10-year median of 48.55. Over the past 10 years, this metric has ranged from a low of 27.74 to a high of 138.32. The Medical Diagnostics & Research industry median EV-to-OCF is 5.91. WuXi XDC Cayman's value of 42.24 is 614.7% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #191 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #191 out of 214 companies for EV-to-OCF. This places WuXi XDC Cayman in the lower half of its industry. The industry median EV-to-OCF is 5.91. WuXi XDC Cayman's value of 42.24 is 614.7% above this benchmark. Historically, WuXi XDC Cayman's own EV-to-OCF has ranged from 27.74 to 138.32 over the past decade. While the company's 10-year median is 48.55 vs. the industry median of 5.91, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 5.91, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current EV-to-OCF of 42.24 is 614.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 5.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current EV-to-OCF is 42.24, which is 13% below median its own 10-year median of 48.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (FRA:L74) has a current EV-to-OCF of 42.24. The current EV-to-OCF is 42.24, which is 13% below median its 10-year median of 48.55 and 614.7% above the Medical Diagnostics & Research industry median of 5.91. WuXi XDC Cayman's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For WuXi XDC Cayman (FRA:L74), the current EV-to-OCF is 42.24 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
55GF Score
Get the complete analysis for FRA:L74
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L74 has been successfully added to your 
